New technology will enable the Animas® pump to receive glucose readings and display this information on the pump's color screen.Access to real-time glucose readings and trending in addition to receiving alerts for low and high glucose readings.Real-time readings displayed on the pump screen will not only allow users to make more timely adjustments to their insulin delivery – it will eliminate a separate receiver, reducing the amount of equipment required to use CGM and the pump system.Pleased to work with Animas Corporation to help people with diabetes live better, longer lives.Of the reasons that we chose to work with Animas is their open architecture philosophy," explains Terrance H.President and Chief Executive Officer of De.Expect future innovations wille from bothpanies – maximizing choices in glucose monitoring and insulin delivery methods.A chronic disease that requires 24/7 attention.Such as insulin pumps and CGM can help reduce some of the burden on the patients.Animas® insulin pump allows users to quickly increase or decrease their insulin amounts with just a few button presses, based on their blood glucose levels, what they eat, activity and metabolic influences.SEVEN, the only approved seven day CGM system, measures glucose throughout the day and night, allowing users to see trends and patterns in glucose readings.Future pump technology with CGM can give users more powerful tools to better manage their diabetes – and in the long term help prevent theplications associated with the disease.Terms of the agreement, Animas will contribute up to $750,000 to De to offset certain development, clinical and regulatory expenses.Agreement is non-exclusive and does not impact either party's existing third party development agreements.The integrated system will be available to patients in 2009 or early 2010.Inc.Headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for people with diabetes.May 31, 2007, the FDA approved De's second generation continuous glucose monitor, the SEVEN, and De is now in national distribution with this device.Recent approval allows for the use of the SEVEN by adults with diabetes for up to seven consecutive days to detect trends and track glucose patterns, to aid in the detection of hypoglycemia and hyperglycemia and to facilitate acute and long-term therapy adjustments.Statement Regarding Forward Looking Statements This press release contains forward-looking statements concerning the development and anticipated launch of a product which integrates De continuous glucose monitoring technology into the Animas insulin pump.Statements are based on De's current expectations and beliefs concerning future developments and their potential effects on De.Can be no assurance that future developments affecting De will be those that it has anticipated.Is a medical devicepany with a limited operating history.Thepany's products is subject to numerous risks and uncertainties, including a lack of acceptance in the marketplace by physicians and patients, the inability to manufacture products inmercial quantities at an acceptable cost, possible delays in thepany's development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources.Of these risks and uncertainties, in addition to other risks, are more fully described in thepany's annual report on Form 10-K for the period ending December 31, 2006, as filed with the Securities and Exchangemission on February 27, 2007, thepany's quarterly report on Form 10-Q for the period ending September 30, 2007, as filed with the Securities and Exchangemission on October 30, 2007, and its other filings with the Securities and Exchangemission from time to time.One or more of these risks or uncertainties materialize, or should any of thepany's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.Undertakes no obligation to publicly update or revise any forward-looking statements.Related News Items > Source: De Issuer of this News Release is solely responsible for its content.Please address inquiries directly to the issuingpany.Market Research mercial Insight: Antidiabetics Patent expiries and cost containment initiatives balanced by pipeline products" Rmended Reports > > > > > > > > > Copyright 1999-2008 The Healthcare Sales & Marketing Network.Read more Merck agrees to settle 27,000 vioxx lawsuits for $4.85b
Get more Correspondence: aspirin and hormone therapy for prostate cancer
